Compare BioNano Genomics Inc (BNGO) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Prudential PLC — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Prudential PLC trades at $27.46 (market cap $34.02B). The key difference: Prudential PLC is far larger — about 2490.5× BioNano Genomics Inc's market cap, and Prudential PLC pays a 1.94% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PUK | |
|---|---|---|
Market Cap | $13.66M | $34.02B |
Sector | Health | Financials |
52-Week High | $4.92 | $33.61 |
52-Week Low | $1.06 | $24.98 |
Enterprise Value | $16.26M | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Prudential PLC (PUK) trades at $27.495, down 2.57% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and robust cash flow from operations of $3.61B in 2024. Recent earnings beat expectations in Q4 2025, though Q4 2024 missed. The stock faces headwinds from China regulatory news impacting Asian operations, but analyst consensus remains 50% buy.
The outlook is mixed: attractive valuation and profitability support upside, but regulatory risks in China and bearish technicals pose near-term challenges. Investors should weigh strong cash generation and earnings beats against geopolitical exposures and market sentiment pressures for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
